Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin, Fludarabine, and IL-2 in Children with Untreated AML or MDS
NCT00002798Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 1996
- Primary completion
- Sep 2006
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin, fludarabine, aldesleukin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Started Aug 1996; status: completed.
02
Drugs
idarubicinfludarabinealdesleukin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00002798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002798.